Why is this study being conducted?
The purpose of this study is to evaluate a potential new treatment for focal segmental glomerulosclerosis (FSGS). FSGS is a progressive kidney disease where the filters (glomeruli) of the kidneys become inflamed and are damaged by scarring. This makes the filters ‘leaky’ over time and allows protein from the blood to collect in the urine (proteinuria).
Who is eligible to participate in this study?
You may be eligible if you:
- Are between 18 and 80 years of age
- Have primary FSGS or FSGS of undetermined cause, confirmed through a kidney biopsy within 7 years of screening, or documentation of genetic FSGS, diagnosed within 7 years of screening
Applicants who express interest in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be up to 122 weeks and you will have about 13 trial visits.
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You will be assigned to receive either study drug or placebo (non-active medication), to be taken twice a day by mouth.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for travel associated with each study visit.
Contact Haewon Park
For more information about this clinical trial contact:
Haewon Park, Clinical Trial Coordinator.
0481 062 298 clinicaltrialunit@griffith.edu.au
GU HREC #2025/046
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials